Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Colin Wilborn x
Clear All Modify Search
Restricted access

Darryn S. Willoughby, Colin Wilborn, Lemuel Taylor and William Campbell

This study examined the effects of an aromatase-inhibiting nutritional supplement on serum steroid hormones, body composition, and clinical safety markers. Sixteen eugonadal young men ingested either Novedex XT™ or a placebo daily for 8 wk, followed by a 3-wk washout period. Body composition was assessed and blood and urine samples obtained at weeks 0, 4, 8, and 11. Data were analyzed by 2-way repeated-measures ANOVA. Novedex XT resulted in average increases of 283%, 625%, 566%, and 438% for total testosterone (P = 0.001), free testosterone (P = 0.001), dihydrotestosterone (P = 0.001), and the testosterone:estrogen ratio (P = 0.001), respectively, whereas fat mass decreased 3.5% (P = 0.026) during supplementation. No significant differences were observed in blood and urinary clinical safety markers or for any of the other serum hormones (P > 0.05). This study indicates that Novedex XT significantly increases serum androgen levels and decreases fat mass.

Restricted access

Colin Wilborn, Lem Taylor, Chris Poole, Cliffa Foster, Darryn Willoughby and Richard Kreider

The purpose of this study was to determine the effects of an alleged aromatase and 5-α reductase inhibitor (AI) on strength, body composition, and hormonal profiles in resistance-trained men. Thirty resistance-trained men were randomly assigned in a double-blind manner to ingest 500 mg of either a placebo (PL) or AI once per day for 8 wk. Participants participated in a 4-d/wk resistance-training program for 8 wk. At Weeks 0, 4, and 8, body composition, 1-repetition-maximum (1RM) bench press and leg press, muscle endurance, anaerobic power, and hormonal profiles were assessed. Statistical analyses used a 2-way ANOVA with repeated measures for all criterion variables (p ≤ .05). Significant Group × Time interaction effects occurred over the 8-wk period for percent body fat (AI: –1.77% ± 1.52%, PL: –0.55% ± 1.72%; p = .048), total testosterone (AI: 0.97 ± 2.67 ng/ml, PL: –2.10 ± 3.75 ng/ml; p = .018), and bioavailable testosterone (AI: 1.32 ± 3.45 ng/ml, PL: –1.69 ± 3.94 ng/ml; p = .049). Significant main effects for time (p ≤ .05) were noted for bench- and leg-press 1RM, lean body mass, and estradiol. No significant changes were detected among groups for Wingate peak or mean power, total body weight, dihydrotestosterone, hemodynamic variables, or clinical safety data (p > .05). The authors concluded that 500 mg of daily AI supplementation significantly affected percent body fat, total testosterone, and bioavailable testosterone compared with a placebo in a double-blind fashion.